3-Amino-4-methoxy-3-methylbutan-1-ol | 1376105-62-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Amino-4-methoxy-3-methylbutan-1-ol
• CAS: 1376105-62-2
• 化学式: C₆H₁₅NO₂
• mdl: MFCD21184408
• 分子量: 133.19
• InChiKey: OSKKFJANHDTOGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B<br/>[FR] SULFAMOYL-ARYLAMIDES ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE L'HÉPATITE B
  申请人：JANSSEN R & D IRELAND

  公开号：WO2014131847A1

  公开（公告）日：2014-09-04

  Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R1, R2, R3 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  公式（I）的HBV复制抑制剂包括立体化学异构体形式、盐类、水合物和溶剂合物，其中R1、R2、R3和R4的含义如本文所定义。本发明还涉及制备所述化合物的过程、含有它们的药物组合物以及它们在HBV治疗中单独或与其他HBV抑制剂结合使用的用途。
• GLYOXAMIDE SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
  申请人：Janssen Sciences Ireland UC

  公开号：US20160176817A1

  公开（公告）日：2016-06-23

  Inhibitors of HBV replication of Formula (IA) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X and R 1 to R 6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  本发明涉及一种HBV复制的抑制剂Formula（IA），包括立体化学异构体形式和其盐、水合物、溶剂物，其中X和R1至R6的含义如本文所定义。本发明还涉及制备上述化合物的过程，含有它们的制药组合物及其在HBV治疗中的使用，单独或与其他HBV抑制剂结合使用。
• SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
  申请人：JANSSEN SCIENCES IRELAND UC

  公开号：US20160002155A1

  公开（公告）日：2016-01-07

  Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R 1 , R 2 , R 3 and R 4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  公式（I）中HBV复制抑制剂包括立体化学同分异构体形式，盐、水合物和溶剂化物，其中R1、R2、R3和R4的含义如此处所定义。本发明还涉及制备该化合物的过程，含有它们的制药组合物及其在HBV治疗中的单独使用或与其他HBV抑制剂联合使用。
• Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
  申请人：Janssen Sciences Ireland UC

  公开号：US10125094B2

  公开（公告）日：2018-11-13

  Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R1, R2, R3 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  式 (I) 的 HBV 复制抑制剂 包括其立体异构体、盐、水合物和溶液，其中 R1、R2、R3 和 R4 的含义如本文所定义。 本发明还涉及制备所述化合物的工艺、含有这些化合物的药物组合物以及它们在 HBV 治疗中单独或与其他 HBV 抑制剂联合使用的情况。
• Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
  申请人：Janssen Sciences Ireland UC

  公开号：US10450270B2

  公开（公告）日：2019-10-22

  Inhibitors of HBV replication of Formula (IA) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X and R1 to R6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  HBV 复制抑制剂配方（IA） 包括立体化学异构体形式，及其盐类、水合物、溶液，其中 X 和 R1 至 R6 具有本文所定义的含义。 本发明还涉及制备上述化合物的工艺、含有这些化合物的药物组合物，以及它们在 HBV 治疗中单独或与其他 HBV 抑制剂联合使用的情况。